Basic Terbinafine Information

• INN (International Nonproprietary Name): Terbinafine
• Brand Names Available In Australia: Lamisil; Terbinex; (international packagers include Novartis, Taro and Mylan)
• ATC Code: D01BA02
• Forms & Dosages: Tablets 250 mg oral (blisters 7, 14, 28); Cream 1% topical (tubes 7 g, 15 g, 30 g); Spray 1% topical (15 ml, 30 ml); Granules 125 mg and 187.5 mg unit-dose for paediatric use.
• Manufacturers In Australia: Not specified
• Registration Status In Australia: Not specified
• OTC / Rx Classification: Oral tablets are prescription-only worldwide; topical small-pack formulations are commonly available over the counter in many markets.

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Which recent trials change how prescribers choose terbinafine?

Large international randomised controlled trials and meta-analyses from 2022–2025 consistently show systemic terbinafine 250 mg once daily achieves higher mycological and clinical cure rates for dermatophyte onychomycosis than single-course oral azoles.

Australian cohort studies and hospital dermatology audits mirror the international findings, reporting similar effectiveness against local fungal strains and faster conversion to negative microscopy.

Main Outcomes

What outcomes should patients and GPs expect?

Systemic terbinafine demonstrates superior nail penetration and improved nail clearance at 12–24 weeks compared with single-course azole therapy.

Topical 1% terbinafine cream or spray remains first-line for tinea corporis, cruris and pedis for limited disease, with strong short-term clinical cure and fewer systemic risks.

Safety Observations (TGA Reports)

Are there safety signals to watch for in Australia?

Post-market surveillance including TGA and international pharmacovigilance between 2022–2024 highlights rare but serious hepatic events and taste disturbance linked to systemic terbinafine.

The overall frequency of adverse signals remains low, leading clinicians to favour targeted shorter systemic courses and tighter patient selection to minimise hepatic harm.

These trial findings help Australian prescribers weigh efficacy against TGA safety guidance and PBS prescribing realities when recommending terbinafine.

Clinical Mechanism Of Action

Layman's Explanation

How does terbinafine clear fungal skin and nail infections?

Terbinafine kills common skin and nail fungi by blocking the fungus from making a vital building block of its cell membrane, so the fungal cells die and the infection clears.

That nail penetration explains why oral terbinafine works better for onychomycosis than many topical azoles alone.

Scientific Breakdown

What is happening at a molecular level?

Terbinafine is an allylamine (ATC D01BA02) that inhibits the fungal enzyme squalene epoxidase and blocks ergosterol biosynthesis.

This produces toxic squalene accumulation and ergosterol depletion, disrupting membrane integrity and producing fungicidal activity against dermatophytes.

Oral terbinafine 250 mg once daily achieves keratin-bound concentrations in nail and skin, while topical 1% formulations give high local tissue levels with minimal systemic exposure.

Hepatic metabolism predominates, explaining the need for liver monitoring in systemic use and the interaction profile via hepatic enzymes.

Resistance can arise from mutations in squalene epoxidase, which helps explain occasional loss of susceptibility.

Scope Of Approved & Off-Label Use

Australian Approvals (TGA-Listed, PBS Inclusion)

Can terbinafine be used for all common tinea problems?

Terbinafine is registered globally for onychomycosis and common tinea infections and is supplied as oral 250 mg tablets and topical 1% cream/spray.

Oral therapy is prescription-only, while small-pack topical products are commonly supplied OTC in many countries.

PBS subsidy pathways exist for antifungal therapies, but exact PBS listings and Authority criteria for terbinafine onychomycosis vary and should be checked before prescribing.

Notable Off-Label Trends In Australian Practice

What off-label uses do Australian clinicians choose?

Clinicians sometimes use paediatric granules or weight-based dosing for tinea capitis, low-dose or shorter systemic courses for recurrent tinea, and combined topical regimens for mixed infections.

Rural GPs and pharmacists often rely on local protocols and close pharmacist–GP collaboration when access to dermatology is limited.

Hospital formularies may restrict systemic terbinafine until baseline liver function tests are confirmed.

Dosage Strategy

General Dosing

What is the standard terbinafine dosing most Australians will be given?

Adult systemic dosing is 250 mg once daily for most indications.

Typical durations are 6 weeks for fingernail onychomycosis and 12 weeks for toenail disease.

Topical 1% cream or spray is applied once or twice daily to limited tinea for 1–4 weeks depending on the product and site.

Condition-Specific Dosing (PBS Recommendations)

Are there paediatric, renal or hepatic special instructions?

Paediatric weight-based granules are commonly used: 125 mg for under 20 kg, 187.5 mg for 20–40 kg and 250 mg for >40 kg when indicated.

In renal impairment exercise caution if CrCl is below 50 ml/min and consider alternative therapy where appropriate.

Systemic terbinafine is contraindicated in chronic or active liver disease and dose reduction is not routinely recommended for hepatic impairment.

PBS Authority items for onychomycosis commonly require laboratory confirmation and may impose specific duration rules, so prescribers should check the current PBS Schedule before prescribing.

Safety Protocols

Contraindications (Australian Guidelines)

Who should not take systemic terbinafine?

Absolute contraindications include known hypersensitivity to terbinafine or its excipients and chronic or active hepatic disease.

Pregnancy and breastfeeding are relative contraindications where systemic use is generally avoided and topical therapy considered with caution.

Baseline liver function testing is standard practice for systemic therapy in higher‑risk patients.

Adverse Effects (Post-Market Pharmacovigilance)

What side effects do patients report in the real world?

Common adverse effects include gastrointestinal upset, headache, taste disturbance, rash and pruritus with oral terbinafine.

Topical therapy can cause local irritation, erythema, itching and stinging.

Serious but rare reactions reported to the TGA and international regulators include hepatotoxicity, severe cutaneous adverse reactions, neutropenia and drug‑induced autoimmune phenomena.

Pharmacovigilance advice is to stop systemic terbinafine and check LFTs immediately if jaundice or unexplained systemic symptoms develop.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Can food or drink change how terbinafine works?

No major food interactions alter terbinafine efficacy, and regular dietary caffeine does not change its activity.

Alcohol does not significantly change terbinafine pharmacokinetics, but combined alcohol consumption and systemic terbinafine increases hepatic burden, so patients should be advised to limit alcohol while on treatment.

Drug Combinations To Avoid (TGA Safety Alerts)

Which medicines need checking before starting terbinafine?

Terbinafine inhibits cytochrome P450 2D6 and is hepatically metabolised, so concurrent use with CYP2D6 substrates such as certain antidepressants, antipsychotics and beta‑blockers can increase plasma levels.

Avoid combining terbinafine with other hepatotoxic medicines where possible, and monitor closely if unavoidable.

Special caution is required with warfarin and other anticoagulants because changes in INR have been reported; monitor therapy closely.

Community pharmacists are essential for screening interactions at dispensing, particularly where telehealth prescribers or remote patients are involved.

Patient Experience Analysis

Australian Survey Data

What do Australian patients say about terbinafine treatment?

Clinic and pharmacy-based audits from 2022–24 show high patient satisfaction with nail clearance after systemic terbinafine, but many patients find the visible improvement slow and frustrating.

Interrupted courses due to side effects, uncertainty about topical versus oral roles and concerns about cost when PBS subsidy does not apply are common adherence barriers.

Forum And Pharmacy Trends

What do online forums and pharmacists commonly hear?

Frequent patient questions include “how long until my nails look normal?” and reports of taste disturbance during or after systemic therapy.

Chain and independent pharmacists report many walk-ins for topical terbinafine and a steady stream of telehealth e‑scripts for oral therapy.

Rural community pharmacists often coordinate baseline LFTs with GPs before systemic initiation and guide patients towards generics or PBS pathways to manage cost concerns.

Distribution & Pricing Landscape

National Pharmacy Chains

Where do Australians buy terbinafine?

Topical OTC terbinafine is widely stocked in Chemist Warehouse, Priceline, TerryWhite Chemmart and independent pharmacies across Australia.

Oral 250 mg tablets are dispensed via pharmacies on prescription, with availability across urban and rural outlets.

Online Pharmacy Growth And Telehealth E-Scripts

How has online access changed treatment patterns?

Online pharmacies and telehealth platforms have increased access to treatment through e‑scripts, speeding treatment starts but sometimes complicating remote LFT monitoring.

In our online pharmacy, terbinafine is available without a prescription, with discreet delivery to Australia in 5-14 days.

PBS Vs Private Cost Comparisons

How much will treatment cost patients?

Topical OTC packs are low-cost, while oral terbinafine tablet prices depend on brand and PBS subsidy status.

Where PBS subsidy is not available or Authority criteria are not met, private costs can be substantial and price-sensitive Australians often choose discount chains or generics such as Mylan or Apotex.

Rural pharmacies may face occasional supply delays for specific generics, so counselling on cost-effective brands and PBS procedures is common practice.

Alternative Options

Comparison Table Of PBS And Non-PBS Options

Which alternatives exist if terbinafine is unsuitable?

Alternatives include oral itraconazole or fluconazole for some onychomycosis cases, topical azoles such as clotrimazole or ketoconazole for skin tinea, naftifine and ciclopirox lacquer for nail disease.

Some azoles are PBS‑listed under specific indications while many topical azoles are OTC.

Pros And Cons Checklist

• Terbinafine Pros: Fungicidal against dermatophytes, excellent nail penetration, effective 12‑week toenail regimens.
• Terbinafine Cons: Hepatic risk, taste disturbance, CYP2D6 interactions.
• Topical Pros: Low systemic risk, OTC access for limited disease.
• Topical Cons: Limited efficacy for onychomycosis and extensive disease; lower cure rates with lacquers versus systemic therapy.

Choice depends on infection site, severity, comorbidities and whether PBS subsidy is available.

Regulatory Status

TGA Approval Framework

How does the TGA oversee terbinafine products?

Terbinafine products are registered for specific dermatophyte indications, with topical small packs often available without prescription and oral tablets remaining prescription-only.

The TGA requires accurate product information, ongoing safety monitoring and periodic adverse event reporting, which feed into risk communications to prescribers and pharmacists.

PBS Subsidy Process

How are subsidies granted for terbinafine in Australia?

PBS subsidy decisions rest on clinical and pharmacoeconomic submissions and can impose Authority requirements for conditions such as onychomycosis.

Authority items commonly require laboratory confirmation of fungal infection and prior topical treatment trials before oral terbinafine subsidy is approved.

Prescribers should follow current PBS rules to secure subsidy and advise patients on the likely out‑of‑pocket cost if Authority criteria are not met.

Consolidated FAQ

What are the quick answers patients ask most?

Q1: Can I buy terbinafine cream over the counter?

A1: Yes, small topical packs of terbinafine cream or spray are commonly available OTC in pharmacies.

Q2: Is terbinafine on the PBS?

A2: Some antifungal indications have PBS pathways; check the current PBS Schedule and any Authority criteria for onychomycosis subsidy.

Q3: Do I need blood tests?

A3: Baseline liver function tests are recommended before systemic therapy in high‑risk patients and repeated if symptoms arise.

Q4: How long until nails clear?

A4: Toenails can take many months to look normal; a 12‑week systemic course may be required, but visible improvement can take 6–12 months due to nail growth.

Q5: Can I drink alcohol while taking terbinafine?

A5: Limit alcohol while on systemic terbinafine to reduce hepatic burden; discuss regular alcohol use with your GP or pharmacist for personalised advice.

Visual Guide

Which graphics help patients understand treatment?

Suggested infographics for Australian audiences include a PBS vs private cost bar chart comparing oral terbinafine brands and topical OTC prices.

A decision flowchart showing topical versus systemic therapy with an LFT checkpoint and PBS Authority step is useful for prescribers and patients.

A map showing pharmacy access urban versus rural and telehealth options helps set expectations for delivery and monitoring.

A treatment timeline infographic illustrating a 12‑week systemic course with months-to-visible-improvement for toenails clarifies expectations.

When publishing, cite sources and date‑stamp visuals, and use current TGA and PBS logos where permitted.

Storage & Transport

Household Storage Under Australian Climate

How should patients store terbinafine at home?

Store terbinafine at 15–30°C in a dry place and protect from moisture and light to avoid degradation.

In hot, humid Australian conditions, advise patients not to leave topical creams in cars or in direct sunlight and to keep tubes tightly sealed.

Do not refrigerate or freeze topical forms.

Cold-Chain Logistics For Pharmacies

Do pharmacies need special storage rules?

Cold-chain is not required for terbinafine products, but pharmacies should store stock at ambient conditions, rotate stock to use-by dates and avoid prolonged heat exposure during transport.

Extra care is needed when shipping to remote or rural locations to prevent heat damage in transit.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

What should pharmacists ask and tell patients before dispensing terbinafine?

Use a patient-centred approach to assess comorbidities, current medicines (especially CYP2D6 substrates), alcohol intake, pregnancy/breastfeeding status and PBS access.

Set realistic expectations on timelines for nail improvement, stress the need for baseline LFTs for systemic therapy in high‑risk patients and list urgent warning signs such as jaundice or severe rash.

Reinforce adherence, advise against doubling doses, and document counselling in the patient record.

National Health Authority Recommendations

Which official guidance should prescribers follow?

Follow TGA product information and current state clinical guidelines for prescribing and monitoring terbinafine.

Use PBS Authority rules when seeking subsidy and liaise with local pathology services to ensure timely LFTs where needed.

In rural settings, pharmacists commonly co‑ordinate with GPs and use telehealth referrals for dermatology review where required.

Delivery Across Australia

Closing Notes For Prescribers And Pharmacists

What practical takeaways should clinicians keep in mind?

Systemic terbinafine 250 mg once daily remains the best-evidenced option for dermatophyte onychomycosis and is often preferred where nail involvement is substantial.

Topical 1% terbinafine is first-line for limited tinea corporis, cruris and pedis because of good local cure rates and minimal systemic exposure.

Always check for contraindications, review concomitant medications for CYP2D6 interactions, advise on limiting alcohol and arrange baseline liver function tests in patients at risk.

Where PBS subsidy is sought for onychomycosis, confirm Authority requirements such as laboratory confirmation before prescribing to reduce patient cost and delays.

Document counselling thoroughly and work with local pathology and telehealth services to ensure safe, effective treatment for patients across Australia.